MELF invasion in endometrial cancer as a risk factor for lymph node metastasis

Histopathology

Volumn 58, Issue 6, 2011, Pages 966-973

  Pavlakis, Kitty ^a,b   Messini, Irini ^b   Vrekoussis, Thomas ^c   Panoskaltsis, Theodoros ^b   Chrysanthakis, Dimitris ^b   Yiannou, Petros ^b   Voulgaris, Zannis ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b IASO   (Greece)

^c UNIVERSITY OF CRETE   (Greece)

Author keywords

Endometrioid endometrial carcinoma; Lymph node metastasis; MELF pattern invasion

Indexed keywords

ABDOMINAL HYSTERECTOMY; ADULT; ARTICLE; CANCER INVASION; ENDOMETRIUM CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; RISK FACTOR; SALPINGOOOPHORECTOMY;

ADENOCARCINOMA; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; HYSTERECTOMY; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MYOMETRIUM; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 79956139765     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.03802.x     Document Type: Article

References (17)

1. Papanikolaou A, Kalogiannidis I, Goutzioulis M et al. Pelvic lymphadenectomy as alternative to postoperative radiotherapy in high risk early stage endometrial cancer. Arch. Gynecol. Obstet. 2006; 274; 91-96.
2. Mohan DS, Samuels MA, Selim MA et al. Long-term outcomes of therapeutic pelvic lymphadenectomy for stage I endometrial adenocarcinoma. Gynecol. Oncol. 1998; 70; 165-171.
3. Benedetti Panici P, Basile S, Maneschi F et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J. Natl Cancer Inst. 2008; 100; 1707-1716.
4. Kilgore LC, Partridge EE, Alvarez RD et al. Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol. Oncol. 1995; 56; 29-33.
5. Cragun JM, Havrilesky LJ, Calingaert B et al. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J. Clin. Oncol. 2005; 23; 3668-3675.
6. Alektiar KM, McKee A, Lin O et al. The significance of the amount of myometrial invasion in patients with Stage IB endometrial carcinoma. Cancer 2002; 95; 316-321.
7. Bottke D, Wiegel T, Kreienberg R, Κurzeder C, Sauer G. Stage IB endometrial cancer. Does lymphadenectomy replace adjuvant radiotherapy? Strahlenther. Onkol. 2007; 183; 600-604.
8. Keys HM, Roberts JA, Brunetto VL et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 2004; 92; 744-751.
9. Murray SK, Young RH, Scully RE. Unusual epithelial and stromal changes in myoinvasive endometrioid adenocarcinoma: a study of their frequency, associated diagnostic problems, and prognostic significance. Int. J. Gynecol. Pathol. 2003; 22; 324-333.
10. McKenney JK, Kong CS, Longacre TA. Endometrial adenocarcinoma associated with subtle lymph-vascular space invasion and lymph node metastasis: a histologic pattern mimicking intravascular and sinusoidal histiocytes. Int. J. Gynecol. Pathol. 2005; 24; 73-78.
11. Mutch DG. The new FIGO staging system for cancers of the vulva, cervix, endometrium and sarcomas. Gynecol. Oncol. 2009; 115; 325-328.
12. Stewart CJ, Crook ML, Leung YC, Platten M. Expression of cell cycle regulatory proteins in endometrial adenocarcinoma: variations in conventional tumour areas and in microcystic, elongated and fragmented glands. Mod. Pathol. 2009; 22; 725-733.
13. Stewart CJ, Brennan BA, Leung YC, Little L. MELF pattern invasion in endometrial carcinoma: association with low grade, myoinvasive endometrioid tumours, focal mucinous differentiation and vascular invasion. Pathology 2009; 41; 454-459.
14. Stewart CJ, Little L. Immunophenotypic features of MELF pattern invasion in endometrial adenocarcinoma: evidence for epithelial-mesenchymal transition. Histopathology 2009; 55; 91-101.
15. Ambros RA, Malfetano JH, Mihm MC Jr. Clinicopathologic features of vulvar squamous cell carcinomas exhibiting prominent fibromyxoid stromal response. Int. J. Gynecol. Pathol. 1996; 15; 137-145.
16. Alexander-Sefre F, Nibbs R, Rafferty T et al. Clinical value of immunohistochemically detected lymphatic and vascular invasions in clinically staged endometrioid endometrial cancer. Int. J. Gynecol. Cancer 2009; 19; 1074-1079.
17. Narayan K, Rejeki V, Herschtal A et al. Prognostic significance of several histological features in intermediate and high-risk endometrial cancer patients treated with curative intent using surgery and adjuvant radiotherapy. J. Med. Imaging Radiat. Oncol. 2009; 53; 107-113.